Wedbush Securities’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Wedbush Securities’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-210,914	Closed	-$17K	–	961
2018 Q2	$17K	Buy	210,914 +150,000	+246%	+$44.5K	﹤0.01%	870
2018 Q1	$19K	Sell	60,914 -14,738	-19%	-$22K	﹤0.01%	809
2017 Q4	$125K	Buy	75,652 +1,888	+3%	+$3.25K	0.02%	773
2017 Q3	$106K	Buy	73,764 +31,800	+76%	+$45.2K	0.01%	776
2017 Q2	$68K	Buy	41,964 +32,126	+327%	+$72K	0.01%	788
2017 Q1	$33K	Buy	+9,838	New	+$46.5K	﹤0.01%	819

Other funds holding ANTH

VCM

Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return

Wedbush Securities's ANTH Position: Q3 2018 in Review

Wedbush Securities sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2018, closing a stake of 210,914 shares — an estimated $17K sold.

Wedbush Securities first reported a position in ANTH in Q1 2017 and held it in 6 quarters. The position peaked at $125K in Q4 2017. 1 fund tracked by Wall St. Rank holds ANTH as of Q3 2018.

Wedbush Securities reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Wedbush Securities sold 210,914 Anthera Pharmaceuticals, Inc. shares in Q3 2018, an estimated $17K.
Wedbush Securities first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2017 and held it in 6 quarters.
Wedbush Securities's Anthera Pharmaceuticals, Inc. position peaked at $125K in Q4 2017.
1 fund tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2018.

Based on Wedbush Securities's 13F filing for Q3 2018, filed 13 Nov 2018.